首页> 外文期刊>Forbes >Back From the Morgue
【24h】

Back From the Morgue

机译:从停尸房回来

获取原文
获取原文并翻译 | 示例
           

摘要

Roche holding could do nothing right, it seemed. The venerable Swiss drug-maker―once the world's largest, thanks in part to its invention of Valium―saw seven drugs fail in final-stage trials in the late 1990s. In 1998 the firm recalled a blood pressure drug less than a year after its release. It was expected to be a big seller but was found to have dangerous drug interactions. The same year its new Parkinson's disease drug was linked to three cases of fatal liver failure. In 2001 an obesity drug and a flu drug that the company was counting on for sales growth fell short. That year the firm announced plans to axe 3,000 workers. A humiliating price-fixing scandal in the firm's vitamins unit (now sold) cost it the equivalent of $4 billion in fines and charges between 1999 and 2002. In 2002 Roche hit rock bottom, reporting a loss of $2.95 billion as its huge investment portfolio soured. Last January crosstown rival Novartis swooped in, increasing its stake to just below the level at which Swiss law would force it to make an offer for the remaining shares. Its hope was (and still is) to prod Roche into a megamerger that would create the world's second-largest drug company.
机译:罗氏控股似乎无能为力。这家享有盛誉的瑞士制药商曾经是世界上最大的制药商,部分归功于其发明了Valium,在1990年代后期,有7种药物在最终试验中失败。 1998年,该公司召回了不到一年的血压药物。预期它会是一个大卖家,但被发现存在危险的药物相互作用。同年,其新的帕金森氏病药物与三例致命的肝衰竭有关。 2001年,该公司指望实现销售增长的肥胖药和流感药均未达标。那年,该公司宣布了裁员3000名工人的计划。 1999年至2002年间,该公司维生素部门(现已出售)的价格欺诈丑闻使该公司蒙受了相当于40亿美元的罚款和收费。2002年,罗氏(Roche)触底反弹,由于庞大的投资组合恶化,亏损29.5亿美元。 。去年一月,跨市竞争对手诺华(Novartis)迅速加入进来,将其持股量增加到略低于瑞士法律迫使其提出要约收购要约的水平。它的希望是(现在仍然)促使罗氏成为一家大型合并公司,从而创建世界第二大制药公司。

著录项

  • 来源
    《Forbes》 |2003年第12期|p.274-276|共3页
  • 作者

    Robert Langreth;

  • 作者单位
  • 收录信息 美国《科学引文索引》(SCI);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 世界经济问题;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号